Literature DB >> 16596793

Cannabinoid tolerance and dependence.

A H Lichtman1, B R Martin.   

Abstract

The use of marijuana for recreational and medicinal purposes has resulted in a large prevalence of chronic marijuana users. Consequences of chronic cannabinoid administration include profound behavioral tolerance and withdrawal symptoms upon drug cessation. A marijuana withdrawal syndrome is only recently gaining acceptance as being clinically significant. Similarly, laboratory animals exhibit both tolerance and dependence following chronic administration of cannabinoids. These animal models are being used to evaluate the high degree of plasticity that occurs at the molecular level in various brain regions following chronic cannabinoid exposure. In this review, we describe recent advances that have increased our understanding of the impact of chronic cannabinoid administration on cannabinoid receptors and their signal transduction pathways. Additionally, we discuss several potential pharmacotherapies that have been examined to treat marijuana dependence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16596793     DOI: 10.1007/3-540-26573-2_24

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  55 in total

1.  The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice.

Authors:  Elizabeth A Cairns; Anna-Maria Szczesniak; Alex J Straiker; Pushkar M Kulkarni; Roger G Pertwee; Ganesh A Thakur; William H Baldridge; Melanie E M Kelly
Journal:  J Ocul Pharmacol Ther       Date:  2017-07-18       Impact factor: 2.671

2.  An item response theory modeling of alcohol and marijuana dependences: a National Drug Abuse Treatment Clinical Trials Network study.

Authors:  Li-Tzy Wu; Jeng-Jong Pan; Dan G Blazer; Betty Tai; Maxine L Stitzer; Robert K Brooner; George E Woody; Ashwin A Patkar; Jack D Blaine
Journal:  J Stud Alcohol Drugs       Date:  2009-05       Impact factor: 2.582

3.  Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.

Authors:  Liting Deng; Josée Guindon; Benjamin L Cornett; Alexandros Makriyannis; Ken Mackie; Andrea G Hohmann
Journal:  Biol Psychiatry       Date:  2014-04-25       Impact factor: 13.382

4.  Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans.

Authors:  Deepak Cyril D'Souza; Brian Pittman; Edward Perry; Arthur Simen
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

5.  Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety.

Authors:  Lauren C Harte-Hargrove; Diana L Dow-Edwards
Journal:  Behav Brain Res       Date:  2012-03-05       Impact factor: 3.332

Review 6.  Marijuana dependence: not just smoke and mirrors.

Authors:  Divya Ramesh; Joel E Schlosburg; Jason M Wiebelhaus; Aron H Lichtman
Journal:  ILAR J       Date:  2011

7.  Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.

Authors:  Richard L Suplita; Sarah A Eisenstein; Mark H Neely; Anna M Moise; Andrea G Hohmann
Journal:  Neuropharmacology       Date:  2007-07-19       Impact factor: 5.250

8.  ΔFosB induction correlates inversely with CB₁ receptor desensitization in a brain region-dependent manner following repeated Δ⁹-THC administration.

Authors:  Matthew F Lazenka; Dana E Selley; Laura J Sim-Selley
Journal:  Neuropharmacology       Date:  2013-09-30       Impact factor: 5.250

Review 9.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

10.  Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions.

Authors:  Matthew F Lazenka; Bethany G David; Aron H Lichtman; Eric J Nestler; Dana E Selley; Laura J Sim-Selley
Journal:  Biochem Pharmacol       Date:  2014-08-02       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.